Clinical trial
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura…
NCT00094978 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00094978 |
|---|---|
| Title | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum |
| Official title | Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus, Pleura, Thymus or Mediastinum |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Small Cell, Non-Small-Cell Lung, Esophageal Neoplasms, Mesothelioma |
| Intervention type | Drug |
| Interventions | Depsipeptide, Flavopiridol (alvocidib) |
| Enrollment | 23 |
| Start date | Oct 25, 2004 |
| Primary completion | May 20, 2013 |
| Completion | May 20, 2013 |
| First posted | Oct 29, 2004 |
| Last update posted | Dec 12, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: